Previous 10 | Next 10 |
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- New to The Street , an FMW Media production, will air its corporate interviews, episodes 486 and 487, on Newsmax and the FOX Business Network . The Following Corporate interviews will air on Newsmax, episode 486, Saturd...
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax announces its 484th show line-up, which features five (5) Corporate interviews, airing Saturday, July 01, 2023, 3:30-4:00 PM ET. 1). Biopharmaceutical – Acurx Pharmaceuticals, Inc....
Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET PR Newswire STATEN ISLAND, N.Y. , June 15, 2023 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP), a ...
2023-05-22 14:49:12 ET Summary SER-109 (Vowst) was recently approved by FDA and will be launched in June with the Nestle commercial team. Most of the pipeline has failed in clinical trials. There is one active, albeit early stage clinical program, SER -155. The company bur...
2023-05-16 09:10:30 ET Clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, Acurx Pharmaceuticals ( NASDAQ: ACXP ) enters into a securities purchase agreement with a single institutional investor to pu...
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire STATEN ISLAND, N.Y. , May 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical compa...
2023-05-12 10:33:08 ET Acurx Pharmaceuticals, Inc. (ACXP) Q1 2023 Earnings Conference Call May 12, 2023, 08:00 AM ET Company Participants Rob Shawah - CFO Dave Luci - President and CEO Conference Call Participants Jim Molloy - Alliance Global Partners ...
2023-05-12 07:02:59 ET Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q1 GAAP EPS of -$0.25. The Company ended the quarter, with cash totaling $7.2 million compared to $9.1 million as of December 31, 2022. For further details see: Acurx Pharmaceuticals GAA...
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 12, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage bioph...
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , May 5, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...